Trovagene, Inc., today announced it will expand the clinical collaboration with Genomac Research Institute in Prague, Czech Republic. Trovagene Precision Cancer Monitoring SM technology will be used in two prospective clinical studies for the early detection of emerging oncogene mutations indicative of resistance to targeted therapies used to treat colorectal and lung cancer.
from The Medical News http://ift.tt/1Ca3ELi
from The Medical News http://ift.tt/1Ca3ELi
No comments:
Post a Comment